Levosimendan: A retrospective single-center case series

Journal of Critical Care

Volumn 28, Issue 6, 2013, Pages 1075-1078

  Berry, William T ^a,b   Hewson, Russell W ^b   Langrish, Chris J ^a,b   Mckenzie, Catherine A ^a,b   Barrett, Nicholas A ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ACC; Acute heart failure; AHA; AHF; Cardiogenic shock; Dobutamine; ESC; GSTT; IBM; Levosimendan; Noradrenaline

Indexed keywords

DOBUTAMINE; HYPERTENSIVE FACTOR; LEVOSIMENDAN; NORADRENALIN;

ACUTE HEART FAILURE; AGED; ARTICLE; CASE STUDY; DOSE RESPONSE; FLUID BALANCE; HEART HEMODYNAMICS; HEART INDEX; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION;

ACC; ACUTE HEART FAILURE; AHA; AHF; AMERICAN COLLEGE OF CARDIOLOGY; AMERICAN HEART ASSOCIATION; CARDIOGENIC SHOCK; DOBUTAMINE; ESC; EUROPEAN SOCIETY OF CARDIOLOGY; GSTT; GUYS AND ST.THOMAS' NHS FOUNDATION TRUST; IBM; INTERNATIONAL BUSINESS MACHINES; LEVOSIMENDAN; NORADRENALINE;

AGED; CARDIOTONIC AGENTS; DOBUTAMINE; FEMALE; HEART FAILURE; HEMODYNAMICS; HOSPITAL MORTALITY; HUMANS; HYDRAZONES; INTENSIVE CARE UNITS; MALE; MILRINONE; NOREPINEPHRINE; PYRIDAZINES; RETROSPECTIVE STUDIES; SYMPATHOMIMETICS; TREATMENT OUTCOME;

EID: 84887401553     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2013.06.014     Document Type: Article

References (30)

1. Adams K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am J Heart 2005, 149:209-216.
2. Follath F., Yilmaz M.B., Delgado J.F., et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Int Care Med 2011, 37:619-626.
3. Nieminen M.S., Brutsaert D., Dickstein K., et al. EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology: EuroHeart Failure Survey II (EHFS II): a survey on hospitalised acute heart failure patients: description of population. Eur Heart J 2006, 27:2725-2736.
4. Nieminen M.S., Harjola V.P. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 2005, 96:5G-10G.
5. Goldberg R.J., Samad N.A., Yarzebski J., et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999, 340:1162-1168.
6. Spinar J., Parenica J., Vitovec J., et al. Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Crit Care 2011, 15:R291.
7. Dickstein K., Cohen-Solar A., Filipinos G., et al. ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
8. Böhm M., Link A., Cain D., et al. A beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE) trial. Crit Care Med 2011, 28:940-944.
9. Dargie H.J. The Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385-1390.
10. Petersen J.W., Felker M.G. Inotropes in the management of acute heart failure. Crit Care Med 2008, 36:S106-S111.
11. Thackray S., Easthaugh J., Freemantle N., et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 2002, 4:515-529.
12. Packer M. The search for the ideal positive inotropic agent. N Engl J Med 1993, 329:201.
13. O'Connor C.M., Gattis W.A., Uretsky B.F., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999, 138:78-86.
14. Felker G.M., Benza R.L., Chandler A.B., et al. OPTIME-CHF Investigators: Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003, 41:997-1003.
15. Tachibana H., Cheng H.J., Ukai T., et al. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 2005, 288:H914-H922.
16. Lilleberg J., Nieminen M.S., Akkila J., et al. Effects of a new calcium sensitizer, levosimendan, on hemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998, 19:660-668.
17. Morelli A., Teboul J.L., Maggiore S.M., Vieillard-Baron A., et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 2006, 34:2287-2293.
18. Slawsky M.T., Colucci W.S., Gottlieb S.S., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000, 102:2222-2227.
19. Nieminen M.S., Akkila J., Hasenfuss G., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000, 36:1903-1912.
20. Mebazaa A., Nieminen M.S., Packer M., et al. SURVIVE Investigators: Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007, 297:1883-1891.
21. Follath F., Cleland J.G., Just H., et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360:196-202.
22. Fuhrmann J.T., Schmeisser A., Schulze M.R., et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008, 36:2257-2266.
23. Samimi-Fard S., García-González M.J., Domínguez-Rodríguez A., et al. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol 2008, 127:284-287.
24. Dominguez-Rodriguez A., Samimi-Fard S., Garcia-Gonzalez M.J., et al. Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. Int J Cardiol 2008, 128:214-217.
25. Dominguez-Rodriguez A., Samimi-Fard S., Garcia-Gonzalez M.J., et al. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 2006, 8:723-728.
26. Moiseyev V.S., Põder P., Andrejevs N., et al. RUSSLAN Study Investigators: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002, 23:1422-1432.
27. Delaney A., Bradford C., McCaffrey J., et al. Levosimendan for the treatment of acute severe heart failure; a meta-analysis of randomised controlled trials. Int J Cardiol 2010, 138:281-289.
28. Landoni G., Biondi-Zoccai G., Greco M. Effects of levosimendan on mortality and hospitalisation. A meta-analysis of randomised controlled studies. Crit Care Med 2012, 40:634-646.
29. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):e391-e479.
30. Bota D.P., Bross A., Mélot C., et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286:1754-1758.